Zevra Therapeutics is a specialty pharmaceutical company focused on the discovery and development of treatments for central nervous system and rare disease indications that allow it to target areas with unmet needs. Co.'s prodrug product candidate pipeline is focused on the idiopathic hypersomnia (IH) and other CNS/rare diseases. Co.'s approved product, AZSTARYS®, a once-daily treatment for attention deficit hyperactivity disorder in patients, age six years and older, contains its prodrug, serdexmethylphenidate (SDX). Co.'s primary clinical development product candidate, KP1077, is based on SDX, its prodrug of d-methlyphenidate and is in development for the treatment of IH and narcolepsy. We show 5 historical shares outstanding datapoints in our coverage of ZVRA's shares outstanding history.
Understanding the changing numbers of ZVRA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ZVRA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ZVRA by allowing them to research ZVRA shares outstanding history
as well as any other stock in our coverage universe. |
Free ZVRA Email Alerts:
Video: Shares Outstanding Importance
